Previous close | 14.84 |
Open | 14.84 |
Bid | 14.90 |
Ask | 16.90 |
Strike | 125.00 |
Expiry date | 2024-06-21 |
Day's range | 14.84 - 14.84 |
Contract range | N/A |
Volume | |
Open interest | 88 |
A rise in the use of recreational marijuana use in states that have legalized cannabis appears to be behind a spike in falsified workplace drug tests.
Cheating on drug tests among American workers has surged to its highest level in over 30 years, according to a lab report from Quest Diagnostics Inc (NASDAQ:DGX). The lab reported that approximately 31,000 out of 5.5 million drug tests showed signs of tampering in 2023. Dr. Suhash Harwani, senior director of science for workforce health solutions at Quest, highlighted the lengths some individuals go to subvert the drug-testing process. The steady rate of positive drug tests, combined with an inc
The percentage of employees in the general U.S. workforce whose drug test showed signs of tampering increased by more than six-fold in 2023 versus the prior year, the highest rate ever in more than 30 years of annual reporting. This finding is part of a new analysis of nearly 9.8 million workforce drug tests released today by Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services. To view the full report, visit www.QuestDiagnostics.com/DTI.